Transcatheter aortaklappervervanging bij native aortaregurgitatie — huidige bewijslast en toekomstige ontwikkelingen

Aortic regurgitation (AR) is a common valvular heart disease with an estimated prevalence of greater than 4% among patients aged greater than 65 years in some series. If left untreated, AR is associated with progression to left ventricular dysfunction and death. Surgical aortic valve replacement is considered the gold standard for the management of symptomatic AR. Several dedicated transcatheter heart valves (THVs) are currently in development. In this review, we highlight the current evidence and future studies evaluating outcomes of dedicated THVs for transcatheter aortic valve replacement in AR.